Publications by authors named "H Bry-Gauillard"
Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF/ICSI procedures (DELTA Study).
Eur J Obstet Gynecol Reprod Biol
February 2024
Article Synopsis
- The study evaluated the use and effectiveness of follitropin delta in women undergoing IVF or ICSI, focusing on its safety and dosing patterns in clinical practice after one treatment cycle.
- Conducted in France across 14 centers, 248 women were treated, with 223 being analyzed; the study highlighted that a significant majority of patients followed a standardized dosing algorithm.
- Key findings included an average of 11.3 oocytes retrieved per patient, a clinical pregnancy rate of 35%, and an ongoing pregnancy rate of 29.6%, indicating good efficacy and safety of follitropin delta in IVF/ICSI treatments.
Late and brief recovery of ovarian function 7 years after Mitotane cessation.
Reprod Biomed Online
September 2023
Study Question: Is the total number of oocytes retrieved with dual ovarian stimulation in the same cycle (duostim) higher than with two consecutive antagonist cycles in poor responders?
Summary Answer: Based on the number of total and mature oocytes retrieved in women with poor ovarian response (POR), there is no benefit of duostim versus two consecutive antagonist cycles.
What Is Known Already: Recent studies have shown the ability to obtain oocytes with equivalent quality from the follicular and the luteal phase, and a higher number of oocytes within one cycle when using duostim. If during follicular stimulation smaller follicles are sensitized and recruited, this may increase the number of follicles selected in the consecutive luteal phase stimulation, as shown in non-randomized controlled trials (RCT).
Objectives: The objective of the study was to compare the live birth rate and miscarriage rate after fresh embryo transfer (Fresh ET) when patients are treated either with oral dydrogesterone or micronized vaginal progesterone (MVP) as luteal phase support (LPS). The vaginal route is still preferred, despite the discomfort for the patients and recent RCTs showing similar results for dydrogesterone and MVP.
Methods: All 556 consecutive Fresh ET after autologous IVF procedure, from December 2011 to March 2013 in one centre in France were included.
Research Question: How should the fertility of a woman with persistent specific ovarian dysfunction after long-term mitotane exposure be managed?
Design: Case report. A 33-year-old woman who underwent surgery for adrenocortical carcinoma and treated with mitotane was referred for infertility. She rapidly became amenorrhoeic while taking mitotane, a condition that persisted for 5 years after cessation.